Stock A086060 GENEBIOTECH CO. ,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials GeneBioTech Co. ,Ltd

Equities

A086060

KR7086060001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 24/06/2024 am IST 		5-day change 1st Jan Change
3,945 KRW -0.25% Intraday chart for GeneBioTech Co. ,Ltd -4.25% -9.52%
2023 GeneBioTech Co. ,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2018 GL Pharm Tech Corp. announced that it has received KRW 2 billion in funding from Daone Chemical Co., Ltd., Genebiotech Co., Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 35,002 48,391 49,511 45,119 34,356 37,542
Enterprise Value (EV) 1 20,992 40,677 27,727 37,631 31,295 28,028
P/E ratio 13 x 57.1 x -21.1 x -93.1 x 22.6 x 14.5 x
Yield 0.74% 0.53% 0.52% - - -
Capitalization / Revenue 0.56 x 0.83 x 0.84 x 0.72 x 0.42 x 0.47 x
EV / Revenue 0.33 x 0.7 x 0.47 x 0.6 x 0.38 x 0.35 x
EV / EBITDA 2.7 x 16.1 x 29.2 x 47.6 x 11 x 5.28 x
EV / FCF 3.22 x -9.4 x -4.58 x -6.57 x -5.56 x 5.08 x
FCF Yield 31.1% -10.6% -21.8% -15.2% -18% 19.7%
Price to Book 0.73 x 1.03 x 1.1 x 1.03 x 0.75 x 0.78 x
Nbr of stocks (in thousands) 8,611 8,611 8,611 8,611 8,611 8,611
Reference price 2 4,065 5,620 5,750 5,240 3,990 4,360
Announcement Date 19/03/19 16/03/20 17/03/21 17/03/22 16/03/23 15/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 62,809 58,245 59,119 62,814 82,759 79,477
EBITDA 1 7,774 2,527 950.2 791.3 2,843 5,311
EBIT 1 6,271 841.4 -1,097 -453.1 1,557 3,973
Operating Margin 9.98% 1.44% -1.86% -0.72% 1.88% 5%
Earnings before Tax (EBT) 1 5,441 350.1 -419.8 -837.8 1,815 3,374
Net income 1 2,683 846.8 -2,341 -484.4 1,523 2,591
Net margin 4.27% 1.45% -3.96% -0.77% 1.84% 3.26%
EPS 2 311.6 98.34 -271.9 -56.26 176.9 301.0
Free Cash Flow 1 6,528 -4,328 -6,050 -5,730 -5,633 5,514
FCF margin 10.39% -7.43% -10.23% -9.12% -6.81% 6.94%
FCF Conversion (EBITDA) 83.97% - - - - 103.82%
FCF Conversion (Net income) 243.32% - - - - 212.78%
Dividend per Share 2 30.00 30.00 30.00 - - -
Announcement Date 19/03/19 16/03/20 17/03/21 17/03/22 16/03/23 15/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 14,010 7,714 21,784 7,488 3,061 9,514
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 6,528 -4,328 -6,050 -5,730 -5,633 5,514
ROE (net income / shareholders' equity) 6.12% -0.06% -0.13% -1.03% 3.4% 5.51%
ROA (Net income/ Total Assets) 5.93% 0.75% -1.05% -0.46% 1.56% 3.82%
Assets 1 45,236 1,13,176 2,22,051 1,04,735 97,386 67,870
Book Value Per Share 2 5,570 5,450 5,231 5,104 5,310 5,610
Cash Flow per Share 2 1,165 653.0 1,021 863.0 863.0 1,016
Capex 1 558 2,266 4,378 3,102 1,155 530
Capex / Sales 0.89% 3.89% 7.41% 4.94% 1.4% 0.67%
Announcement Date 19/03/19 16/03/20 17/03/21 17/03/22 16/03/23 15/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GENEBIOTECH CO. ,LTD Stock GeneBioTech Co. ,Ltd
-9.52% 24.32M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+46.45% 654B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
ASTRAZENECA PLC Stock AstraZeneca PLC
+19.15% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+3.89% 229B
NOVARTIS AG Stock Novartis AG
+14.05% 219B
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A086060 Stock
  4. Financials GeneBioTech Co. ,Ltd